QuanDx Company

QuanDx develops life science reagents and molecular diagnostic kits for applications in various diseases.
QuanDx Inc. was founded in September 2010 in New York City, NY, USA. In Jan., 2013, QuanDx moved to Bay area of San Francisco, California, the heart of biotech industry. QuanDx’ vision is to develop and commercialize innovative and unique research / clinical diagnostic assays based on proprietary technology for use in clinical and research laboratories worldwide.
Our patented technology is based on innovative Yin-Yang Probes which offer multiple benefits in the design and function of molecular based assays.
The first commercial product lines will comprise of Q-Fusion leukemia screening kits, AML/ALL leukemia screening kits, BCR-ABL P210/P190 One-tube Quant kits. The ability to detect cancer specific fusion genes is important not only in cancer research, but also increasingly in clinical settings to ensure that correct diagnosis is made and the optimal personalised treatment is chosen. It is the objective of QuanDx to offer a simpler and cost-effective solution for the detection of these important fusion genes.

Investors

Headquarters: Menlo Park
Funding Status: undisclosed
Employee Number: 1-10
Investment Stage: N/A
Number Of Exists: N/A
Technology: Personalized Diagnostics
Investor Type: N/A
Founded Date: 2010
Industry: Precision Medicine
Register and Claim Ownership